Tamoxifen and aromatase inhibitors for relapse of tubo-ovarian high-grade serous cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Tamoxifen and aromatase inhibitors for relapse of tubo-ovarian high-grade serous cancer

Published:2021-04-30 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Gao Ya¹,Yang Kelu¹,Shi Shuzhen¹,Wang Jing²,Zhang Junhua³,Tian JinHui¹

Affiliation:

1. Evidence-Based Medicine Center, School of Basic Medical Sciences; Lanzhou University; Lanzhou City China

2. Department of Obstetrics and Gynecology; The First Hospital of Lanzhou University; Lanzhou China

3. Evidence-Based Medicine Center; Tianjin University of Traditional Chinese Medicine; Tianjin China

Publisher

Wiley

Subject

Pharmacology (medical)

Reference59 articles.

1. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology;Aaronson;Journal of the National Cancer Institute,1993

2. The fallopian tube as the origin of non-uterine pelvic high-grade serous carcinoma;Aggarwal;Obstetrician & Gynaecologist,2016

3. Design, synthesis and biological evaluation of imidazole and triazole-based carbamates as novel aromatase inhibitors;Ammazzalorso;European Journal of Medicinal Chemistry,2021

4. Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients;Bell;Gynecologic Oncology,2020

5. The brief pain inventory: revealing the effect of cancer pain;Bennett;Lancet Oncology,2009

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP